Interleukin-33 as a Potential Biomarker for Rheumatoid Arthritis: A Cross-Sectional Study

Article Sidebar

PDF
Published: Nov 25, 2024
DOI: https://doi.org/10.19109/biota.v0i0.22769
Keywords:
Rheumatoid Arthritis (RA), Interleukin-33 (IL-33), DAS-28 ESR, DAS-28 CRP.

Main Article Content

Mays Saleh Khamees
Department of Medical microbiology, University of Al-Kufa, Iraq
Raad Abdulameer Alasady
Department of Medical microbiology, University of Al-Kufa, Iraq
Hashim Ali Alsherees
Department of Medical microbiology, University of Al-Kufa, Iraq

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that affects about 1% of the general population. It is characterized by chronic, progressive, and systemic inflammation. Interleukin-33 (IL-33), is a pro-inflammatory cytokine that is believed to be involved in joint inflammation in RA. This cross-sectional research aims to determine if interleukin-33 (IL-33) could serve as a potential biomarker for RA diagnosis and evaluation of activity of RA. The research involved 132 patients with inflammatory arthritis, and their serum levels of IL-33 and anti-citrullinated peptide antibody (ACPA) were measured using ELISA. Other routine biomarkers, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and rheumatoid factor (RF), were also measured. The median (IQR) of IL-33 was significantly lower in patients with RA [10.576 pg/mL (7.920)] than in those with other types of inflammatory arthritis [12.896 pg/mL (5.700)]. The study also revealed a non-significant difference in IL-33 levels among the four disease activity groups according to DAS-28 ESR and DAS-28 CRP (P = 0.830, P = 0.340, respectively). Additionally, IL-33 had a significant negative correlation with age (P = 0.019) and diabetes mellitus (P = 0.032). To the best of our knowledge, this study is the first to evaluate IL-33 as a diagnostic tool, showing a sensitivity of 59.8% and a specificity of 72% at a cut-off value of ≤11.8207 pg/mL. IL-33 test alone is not sufficient for the diagnosis of RA or differentiating it from other types of inflammatory arthritis. Also, it cannot be used as a routine biomarker for the evaluation of RA activity.

Downloads

Download data is not yet available.

Article Details

How to Cite
Interleukin-33 as a Potential Biomarker for Rheumatoid Arthritis: A Cross-Sectional Study. (2024). Jurnal Biota, 11(1), 28-41. https://doi.org/10.19109/biota.v0i0.22769
Issue
Vol. 11 No. 1 (2025): Jurna Biota 2025
Section
Artikel
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

How to Cite

Interleukin-33 as a Potential Biomarker for Rheumatoid Arthritis: A Cross-Sectional Study. (2024). Jurnal Biota, 11(1), 28-41. https://doi.org/10.19109/biota.v0i0.22769

References

H.-Y. Yap, S. Z.-Y. Tee, M. M.-T. Wong, S.-K. Chow, S.-C. Peh, dan S.-Y. Teow, “Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development,” Cells, vol. 7, no. 10, hlm. 161, Okt 2018, doi: 10.3390/cells7100161.

D. Bhowmik, V. Kola, S. Rao Chamakuri, dan C. Bhattacharjee, “Rheumatoid Arthritis: Introduction,” Nat. Prod. Manag. Arthritic Disord., hlm. 1–25, Agu 2022, doi: 10.2174/9789815050776122010003.

V. Conti et al., “Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics,” Biomolecules, vol. 10, no. 12, hlm. 1672, Des 2020, doi: 10.3390/biom10121672.

H. L. Wright, M. Lyon, E. A. Chapman, R. J. Moots, dan S. W. Edwards, “Rheumatoid Arthritis Synovial Fluid Neutrophils Drive Inflammation Through Production of Chemokines, Reactive Oxygen Species, and Neutrophil Extracellular Traps,” Front. Immunol., vol. 11, hlm. 584116–584116, Jan 2021, doi: 10.3389/fimmu.2020.584116.

Y. F. Medina, R. E. Ruíz-Gaviria, A. Buitrago-Lopez, dan C. Villota, “Physical articular examination in the activity of rheumatoid arthritis: a systematic review of the literature,” Clin. Rheumatol., vol. 37, no. 6, hlm. 1457–1464, Feb 2018, doi: 10.1007/s10067-018-4015-4.

F. Motta et al., “Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis,” RMD Open, vol. 9, no. 3, hlm. e002817, Agu 2023, doi: 10.1136/rmdopen-2022-002817.

L. Carpenter et al., “Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis,” Semin. Arthritis Rheum., vol. 50, no. 2, hlm. 209–219, Apr 2020, doi: 10.1016/j.semarthrit.2019.08.006.

Alkazzaz, “Rheumatoid Arthritis and Psoriasis Vulgaris,” Postgrad. Med. J., vol. 33, no. 380, hlm. 298–298, Jun 2013, doi: 10.1136/pgmj.33.380.298-a.

A. H. K. Al_Badran, H. C. Algabri, K. R. H. Al Saeedi, dan A. M. Alqazzaz, “Incidence of Rheumatoid Arthritis at Marjan Teaching Hospital in Babylon, Iraq (2014–2019),” Med. J. Babylon, vol. 19, no. 3, hlm. 358–361, Jul 2022, doi: 10.4103/mjbl.mjbl_32_22.

B. Gavrila et al., “AB0376 Cartilage oligomeric matrix protein, a biomarker of arthritis, could be useful for predicting the response to biologic therapy in rheumatoid arthritis?,” dipresentasikan pada Abstracts Accepted for Publication, BMJ Publishing Group Ltd and European League Against Rheumatism, Jun 2017, hlm. 1179.3-1180. doi: 10.1136/annrheumdis-2017-eular.1241.

F. Atzeni et al., “AB0689 Metabolic syndrome in ankylosing spondylitis and the effect of anti-tnf therapy,” dipresentasikan pada Abstracts Accepted for Publication, BMJ Publishing Group Ltd and European League Against Rheumatism, Jun 2017, hlm. 1294.3-1294. doi: 10.1136/annrheumdis-2017-eular.1792.

J.-N. Zhu, L.-Y. Nie, X.-Y. Lu, dan H.-X. Wu, “Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria?,” Clin. Chem. Lab. Med. CCLM, vol. 57, no. 11, hlm. 1668–1679, Mei 2019, doi: 10.1515/cclm-2019-0167.

Y. Jiang et al., “Biomarkers (mRNAs and non-coding RNAs) for the diagnosis and prognosis of rheumatoid arthritis,” Front. Immunol., vol. 14, hlm. 1087925–1087925, Feb 2023, doi: 10.3389/fimmu.2023.1087925.

M. Weisman dan T. J. Learch, “Established rheumatoid arthritis,” Atlas Rheum. Arthritis, hlm. 69–90, 2015, doi: 10.1007/978-1-907673-91-7_4.

S. C. Shapiro, “Biomarkers in Rheumatoid Arthritis,” Cureus, vol. 13, no. 5, hlm. e15063–e15063, Mei 2021, doi: 10.7759/cureus.15063.

L. Shervington, A. Darekar, M. Shaikh, R. Mathews, dan A. Shervington, “Identifying Reliable Diagnostic/Predictive Biomarkers for Rheumatoid Arthritis,” Biomark. Insights, vol. 13, hlm. 1177271918801005–1177271918801005, Sep 2018, doi: 10.1177/1177271918801005.

A. Burska, M. Boissinot, dan F. Ponchel, “Cytokines as biomarkers in rheumatoid arthritis,” Mediators Inflamm., vol. 2014, hlm. 545493–545493, 2014, doi: 10.1155/2014/545493.

A. I. M. Khalifa, H. A. E. Atia, dan S. Saad, “Levels of Interleukin 17 , Interleukin 23 and Interleukin 27 in Rheumatoid Arthritis and Osteoarthritis in Egyptian Patients,” Al-Azhar Med. J., vol. 42, no. 4, hlm. 629–642, Okt 2013, doi: 10.12816/0015728.

C. Yuan, “IL-33 in autoimmunity; possible therapeutic target,” Int. Immunopharmacol., vol. 108, hlm. 108887, Jul 2022, doi: 10.1016/j.intimp.2022.108887.

S. Erfurt et al., “Serum IL-33 as a biomarker in different diseases: useful parameter or much need for clarification?,” J. Circ. Biomark., vol. 10, hlm. 20–25, Nov 2021, doi: 10.33393/jcb.2021.2327.

S. Tang et al., “Increased IL-33 in synovial fluid and paired serum is associated with disease activity and autoantibodies in rheumatoid arthritis,” Clin. Dev. Immunol., vol. 2013, hlm. 985301–985301, 2013, doi: 10.1155/2013/985301.

M. Cui et al., “Phosphorescence Enzyme-Mimics for Time-Resolved Sensitive Diagnostics and Environment-Adaptive Specific Catalytic Therapeutics,” ACS Nano, vol. 17, no. 21, hlm. 21262–21273, Nov 2023, doi: 10.1021/acsnano.3c05552.

W.-D. Xu, M. Zhang, Y.-J. Zhang, dan D.-Q. Ye, “IL-33 in rheumatoid arthritis: Potential role in pathogenesis and therapy,” Hum. Immunol., vol. 74, no. 9, hlm. 1057–1060, Sep 2013, doi: 10.1016/j.humimm.2013.06.029.

G.-W. Han et al., “Serum levels of IL-33 is increased in patients with ankylosing spondylitis,” Clin. Rheumatol., vol. 30, no. 12, hlm. 1583–1588, Okt 2011, doi: 10.1007/s10067-011-1843-x.

R. Dwedar, A. R. Awad, dan H. A. Raafat, “Does Novel IL-33 Correlates with TNF-α in RA and SLE ?,” Egypt. J. Med. Microbiol., vol. 24, no. 3, hlm. 13–20, Jul 2015, doi: 10.12816/0024923.

J. Li et al., “New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions,” Dermatology, vol. 233, no. 1, hlm. 37–46, 2017, doi: 10.1159/000471798.

Z. Yang, Y. Liang, W. Xi, C. Li, dan R. Zhong, “Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population,” Clin. Exp. Med., vol. 11, no. 2, hlm. 75–80, Okt 2010, doi: 10.1007/s10238-010-0115-4.

Y. Dong, J. Zhong, dan L. Dong, “IL-33 in Rheumatic Diseases,” Front. Med., vol. 8, hlm. 739489–739489, Sep 2021, doi: 10.3389/fmed.2021.739489.

A. Kumar, “Quality of references reveal the merit of the research,” J. Indian Soc. Periodontol., vol. 26, no. 6, hlm. 519–520, Nov 2022, doi: 10.4103/jisp.jisp_410_22.

E. Elmahdy, A. Salama, N. El-Ragehy, dan A. Ali, “Role of interleukin-33 in patients with chronic hepatitis C in Menoufia University Hospitals, Egypt,” Menoufia Med. J., vol. 30, no. 1, hlm. 249, 2017, doi: 10.4103/mmj.mmj_13_16.

R. MU, H.-Q. HUANG, Y.-H. LI, C. LI, H. YE, dan Z.-G. LI, “Elevated Serum Interleukin 33 Is Associated with Autoantibody Production in Patients with Rheumatoid Arthritis,” J. Rheumatol., vol. 37, no. 10, hlm. 2006–2013, Agu 2010, doi: 10.3899/jrheum.100184.

C. Afferni et al., “The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity,” Front. Immunol., vol. 9, hlm. 2601–2601, Nov 2018, doi: 10.3389/fimmu.2018.02601.

W. A. Verri et al., “IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy,” Ann. Rheum. Dis., vol. 69, no. 9, hlm. 1697–1703, Sep 2010, doi: 10.1136/ard.2009.122655.

A. M. Miller, “Role of IL-33 in inflammation and disease,” J. Inflamm. Lond. Engl., vol. 8, no. 1, hlm. 22–22, Agu 2011, doi: 10.1186/1476-9255-8-22.

Y. Matsuyama et al., “Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response,” Rheumatol. Int., vol. 32, no. 5, hlm. 1397–1401, Mar 2011, doi: 10.1007/s00296-011-1854-6.

Z. Xiangyang, Y. Lutian, Z. Lin, X. Liping, S. Hui, dan L. Jing, “Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis,” Cytokine, vol. 58, no. 1, hlm. 6–9, Apr 2012, doi: 10.1016/j.cyto.2011.12.010.

C. S. Choi et al., “Combined land use of solar infrastructure and agriculture for socioeconomic and environmental co-benefits in the tropics,” Renew. Sustain. Energy Rev., vol. 151, hlm. 111610, Nov 2021, doi: 10.1016/j.rser.2021.111610.

Y. Kageyama, E. Torikai, K. Tsujimura, dan M. Kobayashi, “Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33,” Mod. Rheumatol., vol. 22, no. 1, hlm. 89–93, Feb 2012, doi: 10.3109/s10165-011-0480-1.

M. S. Shalaby, M. I. Salama, R. E. Badr, A. M. Hassan, A. S. Ahmed, dan A. S. Omar, “Serum Interleukin-33 in Rheumatoid Arthritis and its Relation to Disease Activity,” Suez Canal Univ. Med. J., vol. 21, no. 2, hlm. 132–139, Okt 2018, doi: 10.21608/scumj.2018.43593.

Y. Wang, Z. Chen, Y. Huang, L. Yafei, dan S. Tu, “Prognostic Significance of Serum Interleukins and Soluble ST2 in Traditional Chinese Medicine (TCM) Syndrome-Differentiated Rheumatoid Arthritis,” Med. Sci. Monit. Int. Med. J. Exp. Clin. Res., vol. 24, hlm. 3472–3478, Mei 2018, doi: 10.12659/MSM.907540.

Y.-S. Hong et al., “Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis,” J. Korean Med. Sci., vol. 26, no. 9, hlm. 1132–1139, Sep 2011, doi: 10.3346/jkms.2011.26.9.1132.

A. M. Azeez dan I. A. A. Dheep, “Evaluation of Interleukin-33, Interleukin-10 Levels in Rheumatoid Arthritis Patients on Long Term Therapy of Disease-Modifying Antirheumatic Drugs,” SAR J. Pathol. Microbiol., vol. 5, no. 03, hlm. 72–79, Mei 2024, doi: 10.36346/sarjpm.2024.v05i03.006.

M. A. Iedan dan Z. M. M. Al-Rubaei, “Chitotriosidase-1 levels in Iraqi Type 2 Diabetic Patients with Thyroid Disorders,” Ibn AL-Haitham J. Pure Appl. Sci., vol. 32, no. 2, hlm. 45–50, Mei 2019, doi: 10.30526/32.2.2138.

H. Singh et al., “Evaluation of interleukin-33 & sST2 levels in type-2 diabetic mellitus patients with or without metabolic syndrome,” Indian J. Med. Res., vol. 157, no. 5, hlm. 470–476, Mei 2023, doi: 10.4103/ijmr.IJMR_1444_19.

M. Khalili, “Serum levels of interleukin (IL)-33 in patients with ischemic heart disease,” MOJ Immunol., vol. 6, no. 1, 2018, doi: 10.15406/moji.2018.06.00188.

L. Duan, J. Chen, F. Gong, dan G. Shi, “The role of IL-33 in rheumatic diseases,” Clin. Dev. Immunol., vol. 2013, hlm. 924363–924363, 2013, doi: 10.1155/2013/924363.

E. Rivière, J. Sellam, J. Pascaud, P. Ravaud, J.-E. Gottenberg, dan X. Mariette, “Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis,” Arthritis Res. Ther., vol. 20, no. 1, hlm. 122–122, Jun 2018, doi: 10.1186/s13075-018-1628-6.

Most read articles by the same author(s)